

	Page
REPORTS TO THE HOUSE (Cont'd)	
Food and Drug Regulation amended	
"new drug" status	2646
Licensing, compulsory	2637
Marketing, promotional expenses	2619
Medical, pharmacy students instructed	
generic nomenclature	2609
Medical Service Representatives be	
paid by salary not commission	2620
Patent Act	2639-42
Prices differences, comparison before	
purchase	2632
Prices, suggested list, abolished	2647
Professional fee, cost price plus	2633
Research	2625-26
Royalties	2626
Sales Tax, Federal removed prescrip-	
tion drugs	2629
Summary	2651-52
Tariff Board review drug tariff	
structure	2618
Trade Marks Act	2644
Conclusions	2649
Contents	2801-2802
Costs Canadian consumer	2612-14
Costs, prices, factors affecting	2616-45
Drug industry in Canada	2606-12
Other proposals made and considered	2645-49
Physician, hospital, government role	2614-16
Terms of Reference	2603-4
REPRESENTATIVES	
<i>See</i>	
Medical Service Representatives	
RESEARCH	
Ayerst, Research Laboratories	96,202,830,833,844-845, 848,871-876,1802,2207
Basic, applied	197,297,857-860,1379- 82,1434,2318-21,2342-43, 2357-60,2434-45,2622-23